Biovie (BIVI) Share-based Compensation (2013 - 2026)
Biovie (BIVI) posted Share-based Compensation of $1.6 million for Q1 2026, up 691.22% sequentially from $197336.0 in Q4 2025, and up 361.38% YoY from $338412.0 in Q1 2025.
Biovie (BIVI) Share-based Compensation (2013 - 2026) Analysis & Trends
Biovie has reported Share-based Compensation for 13 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Share-based Compensation rose 361.38% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 53.76% YoY) and the FY2025 annual result came in at $1.2 million, down 57.66% from the prior year.
- Share-based Compensation advanced to $1.6 million in Q1 2026 per BIVI's latest filing, from $197336.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.8 million in Q2 2022 and troughed at $118898.0 in Q3 2024.
- A 5-year average of $764860.8 and a median of $705115.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation tumbled 85.29% in 2024, then surged 361.38% in 2026.
- Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then sank by 63.82% to $619701.0 in 2023, then sank by 37.82% to $385328.0 in 2024, then tumbled by 48.79% to $197336.0 in 2025, then surged by 691.22% to $1.6 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.6 million, $197336.0, and $268388.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 256,719.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256,719.00 |
| Jun 30, 2026 | 256,719.00 |
| Mar 31, 2026 | 1.56 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 197,336.00 |
| Dec 31, 2025 | 197,336.00 |
| Sep 30, 2025 | 268,388.00 |
| Sep 30, 2025 | 268,388.00 |
| Jun 30, 2025 | 352,809.00 |
| Jun 30, 2025 | 352,809.00 |
| Mar 31, 2025 | 338,412.00 |
| Mar 31, 2025 | 338,412.00 |
| Dec 31, 2024 | 385,328.00 |
| Dec 31, 2024 | 385,328.00 |
| Sep 30, 2024 | 118,898.00 |
| Sep 30, 2024 | 118,898.00 |
| Jun 30, 2024 | 705,115.00 |
| Jun 30, 2024 | 705,115.00 |
| Mar 31, 2024 | 690,921.00 |
| Mar 31, 2024 | 690,921.00 |